NeuroPaceNPCE -2.03%65 Net Current Asset Value is $0.07 as of Mar. 2026, which is 100% below its 10-year median of 15.85. GuruFocus rates NPCE with a GF Score™ of 65/100 and a GF Value™ of $11.41 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 565 Medical Devices & Instruments companies, NeuroPace ranks worse than 98.58% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
NeuroPace's net current asset value per share for the quarter that ended in Mar. 2026 was $0.07.
The historical rank and industry rank for NeuroPace's Net Current Asset Value or its related term are showing as below:
NPCE'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.04 Med: 15.85 Max: 243.25
Current: 231.5
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of NeuroPace was 243.25. The lowest was 2.04. And the median was 15.85.
NPCE's Price-to-Net-Current-Asset-Value is ranked worse than 98.58% of 565
companies
in the Medical Devices & Instruments industry
Industry Median: 5
vs NPCE: 231.50
NeuroPace (NAS:NPCE) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
NeuroPace Net Current Asset Value Related Terms
NeuroPace Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for NeuroPace's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NPCE vs CLPT, CTKB, CERS: Net Current Asset Value Comparison
For the Medical Devices subindustry, NeuroPace's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where NeuroPace's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.07 mean?
NeuroPace (NPCE) has a Net Current Asset Value of $0.07 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on NeuroPace and its competitors. This is 100% below median its historical median of 15.85. Over the past decade, NeuroPace's Net Current Asset Value has ranged from 2.04 to 243.25. According to the industry distribution chart, NeuroPace ranks #557 out of 565 companies in the Medical Devices & Instruments industry, placing it in the top 98.6%.
Is NeuroPace's Net Current Asset Value too high?
NeuroPace's current Net Current Asset Value of $0.07 is 100% below median its 10-year median of 15.85. Over the past 10 years, this metric has ranged from a low of 2.04 to a high of 243.25. The Medical Devices & Instruments industry median Net Current Asset Value is 5.00. NeuroPace's value of $0.07 is 98.6% below this industry median. Based on the distribution chart, NeuroPace ranks #557 out of 565 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroPace has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's Net Current Asset Value compare to CLPT and CTKB?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #557 out of 565 companies for Net Current Asset Value. This places NeuroPace in the lower half of its industry. The industry median Net Current Asset Value is 5.00. NeuroPace's value of $0.07 is 98.6% below this benchmark. Historically, NeuroPace's own Net Current Asset Value has ranged from 2.04 to 243.25 over the past decade. While the company's 10-year median is 15.85 vs. the industry median of 5.00, NeuroPace has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.00, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroPace's current Net Current Asset Value of $0.07 is 98.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on NeuroPace and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroPace's current Net Current Asset Value is $0.07, which is 100% below median its own 10-year median of 15.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $16.21 — trading 42% above its estimated fair value. The current Net Current Asset Value is $0.07, which is 100% below median its 10-year median of 15.85 and 98.6% below the Medical Devices & Instruments industry median of 5.00. NeuroPace's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For NeuroPace (NPCE), the current Net Current Asset Value is $0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $16.21 is trading 42% above its estimated GF Value™ of $11.41.
GuruFocus considers NeuroPace to be Significantly Overvalued.
Key valuation signals for NPCE:
Net Current Asset Value: $0.07 (100% below median its 10-year median of 15.85)
GF Value™: $11.41 vs. price of $16.21 (42% above fair value)
Industry Position: 98.6% below the Medical Devices & Instruments median (#557 of 565)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
65GF Score
Get the complete analysis for NPCE
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
